Clinical trials: Sepsis and Septic Shock
Sepsis, Severe, Septic Shock
LIPIDS-P Trial Phase I/II Trial
Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis and moderate organ dysfunction and will also…
- Trial name
- LIPIDS-P (NCT03405870)
- Testing
- Smoflipid
- Where
- 3 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Florida
Septic Shock
Rapid Administration of Carnitine in sEpsis
Prior work has shown that exogenous L-carnitine administration enhances glucose and lactate oxidation, attenuates fatty acid toxicity, and improves endothelial-smooth muscle coupling and cardiac mechanical efficiency.
- Trial name
- RACE (NCT01665092)
- Testing
- Levo-Carnitine
- Where
- 14 sites in United States
- Volunteers
- 250 people
- Sponsor
- University of Mississippi Medical Center
Septic Shock, Hypotension
Esmolol to Treat the Hemodynamic Effects of Septic Shock
The main purpose of this study is to determine the effects of controlling the heart rate of patients with septic shock using an intravenous medication called esmolol.
- Conditions
- Septic Shock, Hypotension, Tachycardia
- Trial name
- NCT02369900
- Testing
- Esmolol, Saline
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Beth Israel Deaconess Medical Center
Septic Shock
PK Analysis of Piperacillin in Septic Shock Patients
Antibiotic dosing in septic shock patients poses a challenge for clinicians due to the pharmacokinetic changes seen in this population.
- Trial name
- NCT02306928
- Testing
- Blood draw
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- University of Aarhus
Multiple Organ Failure, Septic Shock
Early Metabolic Resuscitation for Septic Shock
This phase II trial studies how well early metabolic resuscitation therapy works in reducing multi-organ dysfunction in patients with septic shock.
- Conditions
- Multiple Organ Failure, Septic Shock, Severe Sepsis
- Trial name
- NCT03895853
- Testing
- Best Practice, early metabolic resuscitation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Septic Shock
Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148
Septic shock is a potentially life-threatening condition that can result in multi-organ dysfunction syndrome (MODS) and mortality.
- Trial name
- SSAIL (NCT02317549)
- Testing
- LB1148
- Where
- 34 sites in United States, Canada
- Volunteers
- 8 people
- Sponsor
- Leading BioSciences, Inc
Septic Shock
Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
This is a double-blind, randomised, placebo-controlled, two-part adaptive clinical trial. The trial is designed to investigate the efficacy and safety of multiple dosing regimens of selepressin and to confirm the efficacy and…
- Trial name
- SEPSIS-ACT (NCT02508649)
- Testing
- selepressin
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 868 people
- Sponsor
- Ferring Pharmaceuticals
Burns
Pilot Trial of Statin Use in Burn Patients
This is a 90 day study, with patients receiving either oral Rosuvastatin or placebo for up to 28 days. The study will assess the affect of statins administered soon after burn injury on C-reactive protein (CRP) levels, patient…
- Trial name
- BURNSTAT (NCT00978419)
- Testing
- Rosuvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vanderbilt University Medical Center
Septic Shock, Sepsis
Vitamin C and Septic Shock
This is a randomized, double-blind, placebo-controlled clinical trial to compare Vitamin C versus placebo for patients presenting to the ICU with a diagnosis of septic shock.
- Trial name
- NCT03338569
- Testing
- Vitamin C
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- University of Minnesota
Severe Sepsis, Septic Shock
Pharmacokinetic and Biomarker Study of Pioglitazone in Adolescents With Severe Sepsis and Septic Shock
The purpose of this study is to evaluate the pharmacokinetics of pioglitazone and to determine the effect on inflammatory biomarkers for pioglitazone in patients with severe sepsis and septic shock.
- Trial name
- NCT01352182
- Testing
- Pioglitazone hydrochloride
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Septic Shock
A Trial of Vitamin B12 in Septic Shock
This study will randomize 20 septic shock patients to receive either a single 5 gram dose of IV vitamin B12 (Cyanokit® Meridian Medical Technologies, Columbia, MD) versus placebo in addition to standard of care to test the…
- Trial name
- B12 (NCT03783091)
- Testing
- Hydroxocobalamin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medical College of Wisconsin
Toxic Shock Syndrome, Vaccination; Sepsis
rTSST-1 Variant Vaccine Phase 1 First-in-man Trail
Toxic Shock Syndrome (TSS) a severe condition with high morbidity and mortality results from the hosts overwhelming inflammatory response and cytokine storm. Staphylococcal superantigen toxins are the main causative agents.
- Trial name
- rTSST-1 (NCT02340338)
- Testing
- rTSST-1 Variant Candidate Vaccine
- Where
- Austria
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Biomedizinische Forschungs gmbH
Sepsis, Septic Shock
Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial
In this study, we aim to determine whether the combination of Ascorbic Acid (Vitamin C), Thiamine (Vitamin B1), and Corticosteroids improves the trajectory of organ failure and reduces mortality in patients with sepsis and septic…
- Conditions
- Sepsis, Septic Shock, Metabolic Disturbance
- Trial name
- NCT03389555
- Testing
- vitamin C, vitamin B1, hydrocortisone, Normal saline
- Where
- 13 sites in United States
- Volunteers
- 205 people
- Sponsor
- Beth Israel Deaconess Medical Center
Severe Sepsis, Septic Shock
Minimally-Invasive Cardiovascular Hemodynamic Optimization (MiCHO) Versus Early Goal-Directed Therapy (EGDT) in the Management of Septic Shock
Early intervention in the treatment of septic shock, including early goal-directed therapy (EGDT) in the first 6 hours of disease presentation, has been shown to significantly decrease mortality.
- Trial name
- MiCHO (NCT00535821)
- Testing
- Esophageal Doppler monitoring - CardioQ, Deltex Inc, Central line with CVP and continuous ScvO2 monitoring
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Loma Linda University
Septic Shock
Albumin Replacement Therapy in Septic Shock
Albumin is a key regulator of fluid distribution within the extracellular space and possesses several properties beyond its oncotic activity, including binding and transport of several endogenous molecules, anti-inflammatory and…
- Trial name
- ARISS (NCT03869385)
- Testing
- Albutein® 200 g/L or Plasbumin® 20
- Where
- 27 sites in Germany
- Volunteers
- 440 people
- Sponsor
- Jena University Hospital
Shock, Septic
COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2
The study objective is to clarify whether the application of high doses CPFA (coupled plasma-filtration adsorption) in addition to the current clinical practice is able to reduce hospital mortality in septic shock patients in…
- Trial name
- COMPACT-2 (NCT01639664)
- Testing
- High doses CPFA
- Where
- 13 sites in Italy
- Volunteers
- 115 people
- Sponsor
- Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva
Septic Shock, Vasodilatory Shock
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
This trial will be a randomized controlled single-center pilot trial comparing the use of angiotensin II versus standard-of-care (SOC) vasopressor therapy in adult patients with persistent vasodilatory shock despite moderate-dose…
- Trial name
- DARK-Sepsis (NCT05824767)
- Testing
- Angiotensin II
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of New Mexico
Septic Shock
The Randomized Controlled Trial of Inferior Vena Cava Ultrasound-guided Fluid Management in Septic Shock Resuscitation
The primary aim of this study is to evaluate the 30-day mortality outcome of the septic shock patients who are treated with ultrasound-assisted fluid management using change of the inferior vene cava (IVC) diameter during…
- Trial name
- NCT03020407
- Testing
- IVC Ultrasound-guided, Antibiotics, Vasopressor
- Where
- Thailand
- Volunteers
- 211 people
- Sponsor
- Chulalongkorn University
Sepsis, Disease Progression
Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department
To investigate the role of initial venous lactate in predicting the severity progression to overt septic shock and 30-day mortality in non-elderly patients without hemodynamic shock who suspected to have acute infections.
- Conditions
- Sepsis, Disease Progression, Septic Shock, Fatal Outcome
- Trial name
- NCT01947127
- Where
- Thailand
- Volunteers
- 458 people
- Sponsor
- Chulalongkorn University
Septic Shock
Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.
- Trial name
- NCT01612676
- Testing
- FE 202158
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 31 people
- Sponsor
- Ferring Pharmaceuticals